113 Innovative Toys & Games That Will Top Wishlists this Holiday Season! CHICAGO, Nov. 8, 2025 /PRNewswire/ — “Beautified” slime, a dinosaur that hatches itself out of an egg, and wiggly fidget collectibles are among the 113 innovative finalists for the prestigious 2026 Toy of the Year® (TOTY®) Awards, announced today by The Toy Foundation™ (TTF)… Continue reading 2026 Toy of the Year Award Finalists Unveiled at Chicago Toy & Game Fair
Category: Newswire
WAL Investor News: Rosen Law Firm Encourages Western Alliance Bancorporation Investors to Inquire About Securities Class Action Investigation – WAL
NEW YORK, Nov. 8, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Western Alliance Bancorporation (NYSE: WAL) resulting from allegations that Western Alliance Bancorporation may have issued materially misleading business information to the investing public. So what: If you… Continue reading WAL Investor News: Rosen Law Firm Encourages Western Alliance Bancorporation Investors to Inquire About Securities Class Action Investigation – WAL
Zinzino AB (publ.): Zinzino acquires Mexican company Sanki to increase distribution capacity in North America and South America
GOTHENBURG, Sweden, Nov. 8, 2025 /PRNewswire/ — Zinzino has signed an agreement with Mexico-based direct sales company Sanki to acquire the rights to the company’s distributor database and associated customer register, inventory, and IP rights. In addition to the assets, 100% of the shares in Sanki’s subsidiaries in Colombia and Peru are being acquired to… Continue reading Zinzino AB (publ.): Zinzino acquires Mexican company Sanki to increase distribution capacity in North America and South America
Robbins Geller Rudman & Dowd LLP Announces that CarMax, Inc. (KMX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, Nov. 8, 2025 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of CarMax, Inc. (NYSE: KMX) publicly traded securities between June 20, 2025 and September 24, 2025, both dates inclusive (the “Class Period”), have until January 2, 2026 to seek appointment as lead plaintiff of the CarMax class… Continue reading Robbins Geller Rudman & Dowd LLP Announces that CarMax, Inc. (KMX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Zinzino AB (publ.): Zinzino acquires Mexican company Sanki to increase distribution capacity in North America and South America
GOTHENBURG, Sweden, Nov. 8, 2025 /PRNewswire/ — Zinzino has signed an agreement with Mexico-based direct sales company Sanki to acquire the rights to the company’s distributor database and associated customer register, inventory, and IP rights. In addition to the assets, 100% of the shares in Sanki’s subsidiaries in Colombia and Peru are being acquired to… Continue reading Zinzino AB (publ.): Zinzino acquires Mexican company Sanki to increase distribution capacity in North America and South America
Sharing Prosperity in the Intelligent Era: 2025 China International Intelligent Communication Forum Held in Wuxi
WUXI, China, Nov. 8, 2025 /PRNewswire/ — On November 8th, the 2025 China International Intelligent Communication Forum, co-hosted by China Media Group (CMG) and the People’s Government of Jiangsu Province, was held in Wuxi, Jiangsu Province. Continue Reading 2025 China International Intelligent Communication Forum Major projects and initiatives were announced, including the2025 China Cities International Intelligent… Continue reading Sharing Prosperity in the Intelligent Era: 2025 China International Intelligent Communication Forum Held in Wuxi
Cindy Eckert, Founder and CEO of Sprout Pharmaceuticals, to Keynote Harvard Business School’s 2025 Women’s Health Summit
Renowned entrepreneur to headline Harvard Business School’s Women’s Health Summit, bringing together investors, innovators, and changemakers RALEIGH, N.C., Nov. 8, 2025 /PRNewswire/ — Harvard Business School has named Cindy Eckert, Founder and CEO of Sprout Pharmaceuticals, as the Keynote Speaker for the 2025 Women’s Health Summit, taking place Saturday, November 8, at the David Rubenstein Treehouse… Continue reading Cindy Eckert, Founder and CEO of Sprout Pharmaceuticals, to Keynote Harvard Business School’s 2025 Women’s Health Summit
Clinically meaningful pivotal study results for olezarsen in sHTG presented as a late breaker at AHA Scientific Sessions
STOCKHOLM, Nov. 8, 2025 /PRNewswire/ — Sobi® (STO: SOBI) today announced that, the TIMI Study Group today has presented positive results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG) at the American Heart Association 2025 Scientific Sessions. The studies met the primary endpoint, with olezarsen achieving a… Continue reading Clinically meaningful pivotal study results for olezarsen in sHTG presented as a late breaker at AHA Scientific Sessions
inne Debuts at CIIE with Global Launch of Two New Products
SHANGHAI, Nov. 8, 2025 /PRNewswire/ — The 8th China International Import Expo (CIIE) commenced on Nov. 5 in Shanghai, China. The world’s leading children’s nutrition brand inne® was invited to participate, showcasing a range of its innovative achievements on this international stage and seizing the opportunity to share in China’s development alongside global enterprises. Continue… Continue reading inne Debuts at CIIE with Global Launch of Two New Products
AMGEN’S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
Study Also Shows 36% Reduction in Risk of Heart Attack Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Heart Attack and Stroke THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab)… Continue reading AMGEN’S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL